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Gainesville, FL, USAA B S T R A C TObjective: To examine the comparative effectiveness of inhaled
long-acting beta-agonist (LABA), inhaled corticosteroid (ICS), and
ICS/LABA combinations. Methods: We used a retrospective cohort
design of patients older than 12 years with asthma diagnosis in the
Clinical Practice Research Datalink to evaluate asthma-related mor-
bidity measured by oral corticosteroid (OCS) initiation within 12
months of initiating LABAs, ICSs, or ICSs/LABAs. Asthma severity 12
months before drug initiation (use of OCSs, asthma-related hospital
or emergency department visits, and number of short-acting beta-
agonist prescriptions) and during follow-up (short-acting beta-
agonist prescriptions and total number of asthma drug classes)
was adjusted as a time-varying variable via marginal structural
models. Results: A total of 51,103 patients with asthma were
followed for 12 months after receiving ﬁrst prescription for study
drugs from 1993 to 2010. About 92% initiated ICSs, 1% initiated
LABAs, and 7% initiated ICSs/LABAs. Compared with ICSs, LABAsee front matter Copyright & 2015, International S
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ndence to: Ayad K. Ali, Lilly Corporate Center, Indiawere associated with a 10% increased risk of asthma exacerbations
requiring short courses of OCSs (hazard ratio [HR] 1.10; 95% con-
ﬁdence interval [CI] 1.07–1.18). ICS/LABA initiators were 62% less
likely than ICS initiators (HR 0.38; 95% CI 0.12–0.66) and 50% less
likely than LABA initiators to receive OCS prescriptions for asthma
exacerbations (HR 0.50; 95% CI 0.14–0.78). Conclusions: In concord-
ance with current asthma management guidelines, inhaled LABAs
should not be prescribed as monotherapy to patients with asthma.
The ﬁndings suggest the presence of time-dependent confounding
by asthma severity, which was accounted for by the marginal
structural model.
Keywords: asthma, Clinical Practice Research Datalink, long-acting
beta-agonists, marginal structural models.
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Recent years have seen mounting concerns about the safety of
inhaled long-acting beta-agonist (LABA) bronchodilators as asthma
monotherapy, including reports of increased asthma mortality and
poor asthma outcomes [1,2]. Although therapeutic guidelines and
regulatory agencies recommend LABA combination therapy with
inhaled corticosteroids (ICSs) [2,3], there is no evidence that ICSs
protect patients against LABA-induced worsened asthma outcomes.Consequently, in 2011, the Food and Drug Administration required
manufacturers of LABA products to conduct ﬁve long-term, large-
scale randomized, double-masked, clinical trials to further inves-
tigate the safety of ICS/LABA combination therapy in comparison
with ICS monotherapy, with expected ﬁndings to be published in
2017 [4].
Current therapeutic guidelines for the management of asthma
in adults and children are composed of deﬁned therapeutic steps,
where patients move up and down between treatment steps on theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 6 0 – 2 7 0 261basis of disease severity and response to previous treatment [3,5,6].
Consequently, it is important to consider time-dependent con-
founding by asthma severity when studying bronchodilator effects
in retrospective database analyses. Conventional statistical proce-
dures fail to effectively account for this type of confounding, which
is predicted by previous treatment and itself predicts subsequent
treatment [7]. Conversely, marginal structural models (MSMs)
effectively account for this problem under causal effect identiﬁ-
ability assumptions [8,9]. Although it was developed for application
in scenarios with binary exposure variables (e.g., treatment vs. no
treatment or comparison of two treatment options), the technique
can be extended to settings with multiple treatments [9–11]. This
study aimed to apply the MSM to examine the association between
inhaled LABA monotherapy, ICS monotherapy, and ICS/LABA
combination therapy, and prescribing of short courses of oral
corticosteroids (OCSs) for asthma exacerbations in individuals
older than 12 years with asthma in the United Kingdom.Methods
Overview and Study Population
A retrospective inception cohort study was performed within the
UK Clinical Practice Research Datalink (CPRD) between January 4,
1993, and August 10, 2010. The database is described in detail
elsewhere [12–15], and the validity of data for epidemiological
research in respiratory system and research in drug safety has
been established [16–20]. In addition, it is estimated that about
80% of asthmatic patients in the United Kingdom are seen by
general practitioners [21]. Patients with asthma who were con-
tinuously registered with up-to-standard general practices within
the CPRD were randomly selected by a CPRD research liaison.
Presence of asthma was determined using a priori deﬁned Read
Clinical Terms, which are used by the general practitioner to
record the diagnosis and follow-up for each patient. Asthma
diagnosis was deﬁned as having a term for asthma in the clinical,
referral, or test data sets of the CPRD before the index date of a
ﬁrst prescription for the study drugs, or during the maximum
follow-up duration of the study (12 months after the index date).
Patients had to have at least two prescriptions for any of the
three study drug classes within 6 months following a minimum
of 12 months in the database without any of these prescriptions.
They further had to have at least 12 months of follow-up data
available after the ﬁrst study drug prescription (index date). Both
sexes, all race and ethnic groups, and all patients aged 13 to 65
years at index date were considered. Age restrictions were made
because asthma management guidelines deﬁne adult asthmatic
patients as older than 12 years [5], and the prevalence of chronic
obstructive pulmonary disease is more pronounced in the elderly,
complicating the identiﬁcation of patients with true asthma
[22,23]. Exclusion criteria included patients with diagnosis terms
for selected respiratory conditions that were recorded during
study duration (Fig. 1): current smokers or those with a history of
smoking; a history of illicit drug use; participation in a clinical
study, including asthma research; patients with indeterminate
sex; and patients with prescription records for single-device
combination inhaled short-acting beta-agonists (SABAs) and
muscarinic receptor antagonists, single-device combination
inhaled SABAs/ICSs, single-device combination SABAs and mast
cell stabilizers, nonselective beta-blockers including ophthalmic
formulations and antihypertensive products, allergen immuno-
therapy, inhaled betamethasone for lack of dosage bioequiva-
lence information, and omalizumab because only one patient
was prescribed the drug. A comprehensive list of exclusion
criteria with Read Clinical Terms and product codes is availableon request from the corresponding author. Patient disposition,
including exclusion criteria, are described in Figure 1.
Exposure Deﬁnition
The index date for the study was the date associated with the
ﬁrst prescription record for one of the study drug classes (ICSs,
LABAs, or ICSs/LABAs) after the run-in period. For those patients
who had two exposure classes prescribed, the index date is the
earliest of the records. Exposure to study drugs of interest (see
Appendix Table A in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.11.007) was deﬁned on the basis of
logged prescribing records on a monthly basis. The patient was
considered exposed to the study drug at any month he or she
received a prescription, or when the anticipated end date of the
previous prescription exceeds half (415 days) of the month.
Patients who were prescribed study drugs were followed for up
to 12 months from the date of the ﬁrst prescription until the
study end point or any of the following censoring criteria,
whichever came ﬁrst: latest data recording, death, or patient
transfer out of general practice (Fig. 2).
Study End Point
Asthma-related morbidity was deﬁned as initiation of OCSs. In
addition, an algorithm was developed to identify prescriptions for
short courses of OCSs on the basis of whether a prescription was
part of a repeat schedule or a one-off prescription, where the latter
is considered an indicator of a short-course corticosteroids regimen.
Covariates/Confounder Deﬁnition
Read Clinical Terms and product codes were used to identify
confounders during the baseline run-in period and follow-up (see
Appendix Table B in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.11.007). Time-dependent confounders
were updated on a monthly basis and included duration of
practitioner consultation at every prescribing session; prescrip-
tion for inhaled SABAs; number of prescribed asthma medication
classes (including leukotriene receptor antagonists [LTRAs], oral
methylxanthines, mast cell stabilizers, and muscarinic receptor
antagonists); asthma comedications; other comedications;
comorbidities; the annual quarter in which the prescription was
issued; and inhaler device type. The time-ﬁxed confounders
included patient characteristics; practice location; prescription
for OCSs and number of inhaled SABA prescriptions during the
baseline period; presence of an asthma action plan, a diary-like
form in which asthma symptoms and peak ﬂow meter results are
recorded by the patient; and prescription for a compact spacer,
which is used to facilitate the delivery of inhaled medication,
especially when the patient is unable to coordinate inhaling
through the mouth.
Multicategory Exposure MSMs
Baseline characteristics of the three exposure groups were com-
pared using standard univariate statistical methods, including the
chi-square test or the Fisher exact test for categorical variables and
the analysis of variance test for continuous variables. The inci-
dence rates of prescribing OCSs were compared across exposure
groups and were calculated in terms of prescription events per 100
person-years using Kaplan-Meier survival analysis and the sum-
mary (PROC SUMMARY) procedures. Bonferroni correction was
applied to account for multiple comparisons between exposure
groups. Two regression models were constructed, time-dependent
covariate Cox proportional hazards regression (Cox regression)
and MSMs. The consecutive steps for constructing the MSM are
described in Table 1 [8]. Binary logistic regression was used for the
Fig. 1 – Cohort sample disposition. Exclusion numbers are mutually not exclusive, where patients might have more than one
criterion. GPRD, General Practice Research Database; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; MCS, mast
cell stabilizer; MRA, muscarinic receptor antagonist; Rx, prescription; SABA, short-acting beta-agonist.
Fig. 2 – Study proﬁle. ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.
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Table 1 – Steps involved in constructing multicate-
gory marginal structural models.
Step Model
Exposure
selection model
SWEit¼ Π
T
t0
Pr½EiðtÞjEiðt1Þ,Zi
Pr½EiðtÞjEiðt1Þ,Zi,ViðtÞ,Viðt1Þ
Numerator log it Pr½EiðtÞjEiðt1Þ,Z¼β0ðtÞþβ1Eðt1Þþβ2Z
Denominator log it Pr½EðtÞjEðt1Þ,Z,VðtÞ,Vðt1Þ¼β0ðtÞ
þβ1Eðt1Þþβ2Zþβ3VðtÞþβ4Vðt1Þ
Censoring model SWCit¼ Π
T
t0
Pr½CiðtÞjCiðt1Þ,EiðtÞ,Zi
Pr½CiðtÞjCiðt1Þ,EiðtÞ,Zi,ViðtÞ
Numerator log it Pr½CðtÞjCðt1Þ,EðtÞ,Z¼β0ðtÞ
þβ1Cðt1Þ β2EðtÞþβ3Z
Denominator log it Pr½CðtÞjCðt1Þ,EðtÞ,Z,ðVðtÞ¼β0ðtÞ
þβ1Cðt1Þþ β2EðtÞþβ3Zþβ4VðtÞ
Stabilized weights SWE,Cit ¼ΠðSWEitÞ:ðSWCitÞ
Outcome analysis
model
log it λiðtÞ¼Pr½OðtÞ¼1jOðt1Þ¼0,Eðt1Þ,Z
¼β0ðtÞþβ1Eðt,t1Þþβ2Z  SWE,Cit
weighted by β3Vðt,t1Þ
C, censoring status; E, exposure; O, outcome; SW, probability of
exposure given covariate, censoring, and exposure history;
t, current time; t  1, previous time; V, time-dependent confoun-
der; Z, time-independent confounder.
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alized logit link was used for the multicategory exposure selection
model [10,11]. Weighted generalized estimating equation was used
for the outcome analysis model. The stabilized weights are the
product of the weights from the exposure selection and the
censoring models, which achieve balance between exposure
groups. The effect of the exposure on the outcome of interest
was assessed by ﬁtting the MSM that account for time-dependent
confounding that is affected by time-dependent exposure. The
ﬁnal outcome model includes time-varying exposure and baseline
confounders weighted by the inﬂuence of time-dependent con-
founders [8,9]. The presence of time-dependent confounding on
the relationship between exposure and outcome was assessed by
comparing estimates from the MSM with those from the tradi-
tional Cox model [8]. Two-sided tests with α ¼ 0.05 a priori level of
statistical signiﬁcance were used.
The statistical analysis plan was speciﬁed a priori of data
acquisition and analysis. In both models, the hazard ratio (HR)
and the corresponding 95% conﬁdence intervals (CIs) were calcu-
lated for three comparison groups including LABA monotherapy
versus ICS monotherapy, ICS/LABA combination therapy versus
ICS monotherapy, and ICS/LABA combination therapy versus
LABA monotherapy. All statistical analyses were performed using
SAS software (version 9.3) of the SAS System for Windows (2011
SAS Institute, Inc., Cary, NC).Results
Baseline Characteristics of Exposure Groups
There were 51,103 eligible patients with asthma who initiated ICS
(n ¼ 46,928), ICS/LABA (n ¼ 3,461), and LABA (n ¼ 714) therapies.Among the ICS/LABA group, most were prescribed single-device
combination formulations (n ¼ 2,692) compared with separate-
device combination formulations (n ¼ 769) (Fig. 1). Beclometha-
sone accounted for most of the ICS monotherapies (n ¼ 42,328),
followed by budesonide (n ¼ 3,097), ﬂuticasone (n ¼ 1,361),
ciclesonide (n ¼ 94), and mometasone (n ¼ 47). Salmeterol was
prescribed more often than formoterol as an inhaled LABA (n ¼
674 vs. n ¼ 40). Most of the ICS/LABA combination therapy
prescriptions were for ﬂuticasone/salmeterol (n ¼ 2,208) than
for budesonide/formoterol (n ¼ 1,253).
During the follow-up year, most of the ICS initiators continued
on ICS monotherapy. Only 15 (0.03%) ICS initiators switched to
LABA monotherapy and 10,371 (22.1%) switched to ICS/LABA
combination therapy (about 87% as ﬂuticasone/salmeterol com-
bination). Among LABA monotherapy initiators, 478 (67%) sub-
stituted LABA monotherapy with ICS monotherapy; 223 (31.2%)
added ICSs and only 13 (1.8%) continued LABA monotherapy.
A total of 2,045 (59.1%) ICS/LABA combination therapy initiators
switched to ICS monotherapy and about 41% of the combination
therapy initiators continued on this regimen during the follow-up
year. There was no stepping down from ICS/LABA combination
therapy to LABA monotherapy.
Baseline characteristics of exposure groups are given in
Table 2. Females accounted for most of the patients in all groups,
and the mean age for the cohort was 39 years, with younger
patients in the ICS group than in the other two groups. Most of
the patients were obese at baseline, although only one patient in
the LABA group had a diagnosis for obesity. About 89% of the
cohort was nonsmokers; about 10% were reported as former
smokers, and 1% of the patients were passive smokers. Most of
the former smokers and passive smokers were in the LABA group
and the ICS group, respectively.
On average, the duration of registration with the practice was
10 years and was relatively longer in the ICS/LABA combination
therapy group than in either monotherapy groups. Approximately
72%, 64%, and 9% of the patients who were prescribed LABA, ICS,
and ICS/LABA therapy, respectively, had a 10-minute or less
consultation with the prescriber at the time the corresponding
study drugs were prescribed. The vast majority of general practices
were in England (see Appendix Figure A in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.11.007). The prescrib-
ing trend was the highest in the fourth annual quarter and the
lowest in the third annual quarter. This trend was similar across
controller medications with ICS and ICS/LABA, but not among
LABA bronchodilators (see Appendix Figure B in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.11.007).
Most of the asthmatic patients had uncontrolled asthma at
baseline (ICS group 61%; LABA group 60%; ICS/LABA group 52%).
Uncontrolled asthma is deﬁned as having more than two asthma
drug classes or any inhaled SABA prescribed at the index date, or
having any of the following during the baseline year: prescription
for OCS, more than six prescriptions for inhaled SABA, or attend-
ing emergency department or hospitalization for asthma [24].
LTRAs accounted for most of the asthma medications that were
prescribed with LABAs and ICSs/LABAs; however, oral methyl-
xanthines accounted for most of the asthma medications that
were prescribed with ICSs. Systemic antibiotics for respiratory
tract infections accounted for approximately 58% of other med-
ications concurrently prescribed with study drugs (corresponding
to 59% of ICSs, 48% of ICSs/LABAs, and 50% of LABAs). Nasally
administered corticosteroids were the second most prescribed
concurrent medications (25% of ICSs/LABAs, 22% of ICSs, and 21%
of LABAs). About 78% of the prescriptions for immunizations at
the index date were for inﬂuenza vaccines. Pneumococcal poly-
saccharide vaccine accounted for about 4% of concurrent
vaccines. Concurrent immunization was mainly recorded for
ICS-based groups. Atopic conditions contributed to most of the
Table 2 – Patient characteristics for exposure groups.
Characteristic Exposure group (N ¼ 51,103) P*
ICS (n ¼ 46,928;
91.8%)
LABA (n ¼ 714;
1.4%)
ICS/LABA (n ¼ 3,461;
6.8%)
Age (y), mean  SD 37.2  15.3 40.4  15.2 40.0  14.7 o0.001
Sex: female 26,641 (56.8) 404 (56.6) 1,989 (57.5) 0.719
Marital status 0.019
Unmarried 4,537 (9.7) 70 (9.8) 342 (9.9)
Married 6,843 (14.6) 127 (17.8) 556 (16.1)
Unknown 35,548 (75.7) 517 (72.4) 2,563 (74.0)
Weight status 0.645
Nonobese 12 (0.03) 0 2 (0.06)
Obese 63 (0.1) 1 (0.1) 7 (0.2)
Unknown 46,853 (99.8) 713 (99.9) 3,452 (99.7)
Smoking status o0.001
Nonsmoker 40,798 (87.0) 599 (83.9) 2,957 (85.4)
Former smoker 4,385 (9.3) 91 (12.7) 406 (11.7)
Passive smoker 473 (1.0) 5 (0.7) 20 (0.6)
Unknown 1,272 (2.7) 19 (2.7) 78 (2.3)
Prescription payment 0.126
Not exempted 133 (0.3) 2 (0.3) 11 (0.3)
Exempted 521 (1.1) 5 (0.7) 54 (1.6)
Unknown 46,274 (98.6) 707 (99.0) 3,396 (98.1)
Capitation supplement level o0.001
Low 334 (0.7) 4 (0.6) 21 (0.6)
Medium 222 (0.5) 2 (0.3) 14 (0.4)
High 80 (0.2) 1 (0.1) 5 (0.1)
Not applicable 21,396 (45.6) 239 (33.5) 1,264 (36.5)
Unknown 24,896 (53) 468 (65.5) 2,157 (62.4)
Registration duration (mo), mean  SD n ¼ 46,039 n ¼ 691 n ¼ 3,436 0.783
119.8  123.7 117.0  133.0 120.6  131.0
Consultation length (min), mean  SD o0.001
o10 29,819  63.5 515  72.1 2,028  58.6
410 17,075  36.4 196  27.5 1,426  41.2
Unknown 34  0.1 3  0.4 7  0.2
Urgency of visit to practice o0.001
Not urgent visit 46,493 (99.1) 710 (99.5) 3,423 (98.9)
Urgent visit 401 (0.8) 1 (0.1) 31 (0.9)
Unknown 34 (0.1) 3 (0.4) 7 (0.2)
General practice location o0.001
England 37,393 (79.7) 507 (71.0) 2,581 (74.6)
Scotland 4,082 (8.7) 84 (11.8) 256 (7.4)
Wales 4,393 (9.3) 99 (13.8) 440 (12.7)
Northern Ireland 940 (2.0) 24 (3.4) 179 (5.2)
Unknown 120 (0.3) 0 5 (0.1)
Asthma severity at baseline
Prescription for OCS 2,673 (5.7) 46 (0.1) 257 (0.5) o0.001
A&E department visit 126 (0.3) 2 (0.3) 20 (0.6) 0.004
Hospitalization 1 (o0.1) 0 0 0.956
No. of SABA prescriptions, mean  SD 2.2 (7.7) 3.2 (12.0) 2.2 (9.8) 0.004
o6 prescriptions 42,717  91 637  89.2 3,179  91.9 0.057
46 prescriptions 4,211  9.0 77  10.8 282  8.1
Asthma severity at index date
Prescriptions for SABA 25,500 (54.3) 219 (30.7) 1,339 (38.7) o0.001
No. of asthma drug classes, mean  SD 1.5 (0.5) 1.3 (0.5) 2.4 (0.5) o0.001
o2 classes 46,698 (99.5) 703 (98.5) 2,083 (60.2) o0.001
42 classes 230 (0.5) 11 (1.5) 1,378 (39.8)
Asthma controlled at baseline 18,293 (39.0) 429 (60.1) 1,787 (51.6) o0.001
Concurrent asthma drugs
LTRAs 86 (0.2) 14 (2.0) 53 (1.5) o0.001
Oral methylxanthines 99 (0.2) 6 (0.8) 24 (0.7) o0.001
Inhaled MCSs 64 (0.1) 4 (0.6) 2 (0.06) 0.004
Inhaled MRAs 94 (0.2) 5 (0.7) 24 (0.7) o0.001
continued on next page
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Table 2 – continued
Characteristic Exposure group (N ¼ 51,103) P*
ICS (n ¼ 46,928;
91.8%)
LABA (n ¼ 714;
1.4%)
ICS/LABA (n ¼ 3,461;
6.8%)
Other concurrent medications
Antibiotics for RTIs 4,509 (9.6) 54 (7.6) 306 (8.8) 0.065
Antivirals for RTIs 6 (0.01) 0 0 0.765
Nasal CSs 1,686 (3.6) 23 (3.2) 164 (4.7) 0.002
Nasal MCSs 15 (0.03) 2 (0.3) 0 o0.001
Nasal antihistamines 17 (0.04) 0 0 0.469
Nasal decongestants 17 (0.04) 0 0 0.469
Antitussives 161 (0.3) 2 (0.3) 8 (0.2) 0.528
Selective beta-1–blockers 116 (0.2) 2 (0.3) 13 (0.4) 0.350
Oral 115 (0.2) 2 (0.3) 13 (0.4) 0.335
Ophthalmic 1 (o0.1) 0 0 0.956
NSAIDs 288 (0.6) 5 (0.7) 32 (0.9) 0.083
Aspirin 145 (0.3) 7 (1.0) 26 (0.7) o0.001
Acetaminophen 191 (0.4) 2 (0.3) 21 (0.6) 0.181
Opioid analgesics 546 (1.2) 11 (1.5) 73 (2.1) o0.001
Oral cholinergics 1 (o0.1) 0 0 0.956
Concurrent immunizations
Inﬂuenza vaccine 154 (0.3) 2 (0.3) 24 (0.7) 0.002
Pneumococcal PS vaccine 6 (0.01) 0 3 (0.1) 0.006
Other vaccines 37 (0.1) 0 4 (0.1) 0.570
Annual quarter at index date 0.256
First (January–March) 11,635 (24.8) 160 (22.4) 902 (26.1)
Second (April–June) 12,230 (26.0) 176 (24.7) 876 (25.3)
Third (July–September) 10,767 (23.0) 182 (25.5) 779 (22.5)
Fourth (October–December) 12,296 (26.2) 196 (27.4) 904 (26.1)
Comorbidities
Atopic conditions 1,697 (3.6) 29 (4.1) 120 (3.5) 0.731
Allergic rhinosinusitis 968 (2.1) 13 (1.8) 66 (2.0) 0.749
Allergic conjunctivitis 25 (0.05) 2 (0.3) 2 (0.06) 0.041
Atopic dermatitis 282 (0.6) 4 (0.5) 18 (0.5) 0.830
Psoriasis 26 (0.06) 1 (0.1) 2 (0.06) 0.641
Respiratory allergies 7 (0.01) 0 0 0.732
Other allergies 448 (1.0) 10 (1.4) 35 (1.0) 0.461
RTIs 1,139 (2.4) 15 (2.1) 76 (2.2) 0.599
Otitis media 31 (0.07) 0 0 0.251
Pharyngolaryngitis 148 (0.3) 3 (0.4) 11 (0.3) 0.884
Inﬂuenza 53 (0.1) 1 (0.1) 1 (0.03) 0.334
Bronchitis 3 (0.01) 0 0 0.875
Pneumonia 4 (0.01) 0 2 (0.06) 0.034
Other infections 610 (1.3) 8 (1.1) 44 (1.3) 0.907
Psychosocial pathologies
Anxiety 618 (1.3) 14 (2.0) 83 (2.4) o0.001
APD 15 (0.03) 0 2 (0.06) 0.641
Depression 1 (0.01) 0 0 0.875
Other conditions 129 (0.3) 1 (0.1) 14 (0.4) 0.294
Tranquilizer use 21 (0.04) 1 (0.1) 4 (0.1) 0.115
Antipsychotic use 65 (0.1) 3 (0.4) 11 (0.3) 0.006
Antidepressant use 32 (0.07) 0 5 (0.1) 0.210
484 (1.0) 10 (1.4) 65 (1.9) o0.001
Asthma action plan o0.001
Available 564 (1.2) 0 74 (2.1)
Not available 1 (o0.1) 0 0
Unknown 46,363 (98.8) 714 (100) 2,287 (97.9)
Asthma medication compliance 0.735
Satisfactory 101 (0.2) 0 8 (0.2)
Unsatisfactory 27 (0.1) 0 2 (0.1)
Unknown 46,800 (99.7) 714 (100) 3,451 (99.7)
General compliance level 0.720
Good 40 (0.1) 1 (0.1) 5 (0.1)
continued on next page
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Table 2 – continued
Characteristic Exposure group (N ¼ 51,103) P*
ICS (n ¼ 46,928;
91.8%)
LABA (n ¼ 714;
1.4%)
ICS/LABA (n ¼ 3,461;
6.8%)
Poor 7 (0.01) 0 0
Unknown 46,881 (99.9) 713 (99.9) 3,456 (99.9)
Inhaler device type o0.001
pMDI 37,230 (79.3) 527 (73.8) 1,088 (31.4)
BAI 5,433 (11.6) NA NA
DPI 4,158 (8.9) 187 (26.2) 1,517 (43.8)
Unknown 107 (0.2) 0 856 (24.8)
Aerosol 42,696 (91.0) 527 (73.8) 1,823 (52.7) o0.001
Powder 4,169 (8.9) 187 (26.2) 1,638 (47.3)
Unknown 63 (0.1) 0 0
Spacer was prescribed 4,944 (10.5) 23 (3.2) 230 (6.6) o0.001
Nebulizer was prescribed 36 (0.08) 0 1 (0.03) 0.462
Note. Numbers and percentages are reported unless otherwise speciﬁed.
A&E, accident and emergency; APD, affective personality disorder; BAI, breath actuated inhaler; DPI, dry powder inhaler; ICS, inhaled
corticosteroid; LABA, long-acting beta-agonist; LTRA, leukotriene receptor antagonist; MCS, mast cell stabilizer; MRA, muscarinic receptor
antagonist; NA, not applicable/available; NSAIDs, nonsteroidal anti-inﬂammatory drugs; OCS, oral corticosteroid; pMDI, pressurized metered
dose inhaler; PS, polysaccharide; RTI, respiratory tract infection; SABA, short-acting beta-agonist.
* The chi-square test or the Fisher exact test was used for categorical characteristics, and the analysis of variance test was used for continuous
characteristics.
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3.6%; and ICS/LABA group 3.5%) followed by respiratory tract
infections (ICS group 2.4%; ICS/LABA group 2.2%; and LABA group
2.1%) and psychopathologies (ICS/LABA group 2.4%; LABA group
2%; and ICS group 1.3%). Information about the presence of a
personalized asthma action plan and recorded therapy compli-
ance level was sparsely available for ICS-based groups.
Most of the prescribed exposures were in inhaled aerosol form
(ICS group 91%; LABA group 74%; and ICS/LABA group 53%)
compared with inhaled dry powders (ICS/LABA group 47%; LABA
group 26%; and ICS group 9%). Most of the asthmatic patients did
not receive a nebulizer or holding chamber at exposure initiation
date; however, about 10% of ICS initiators had spacer devices
prescribed at baseline compared with 6.6% and 3.2% of ICS/LABA
and LABA initiators, respectively. In addition, although most of
the patients did not receive nebulizers, nebulizers were mainly
prescribed for ICS monotherapy initiators.
Incidence of OCS Initiation for Asthma Exacerbations
Table 3 lists incidence rates and average time to prescribing the ﬁrst
OCS after exposure to study drugs. The study population received a
total of 7108 OCS prescriptions during the follow-up year, 91.4% of
which were for short courses for asthma exacerbations.Table 3 – IRs and average time-to-event of asthma exace
Exposure group
OCS
No. of cases IR (95% CI)* TTE
ICS 1321 10.6 (10.0–11.2) 351.
LABA 29 19.9 (13.8–28.6) 340.
ICS/LABA 138 17.7 (14.9–20.9) 343.
CI, conﬁdence interval; ICS, inhaled corticosteroid; IR, incidence rate; LA
time-to-event in days.
* Cases per 100 person-years.The incidence of prescribing OCSs (in cases per 100 person-
years) was higher in LABA initiators (19.9) than in ICS/LABA (17.7)
or ICS (10.6) initiators. Likewise, LABA initiators had a higher
incidence of being prescribed short courses of OCSs (18.5) than
did initiators of ICS-based therapies (ICS/LABA group 14.8; ICS
group 9.8). Figure 3 indicates a statistically signiﬁcant difference
in the probability of receiving prescriptions for regular and short
courses of OCSs among all exposure groups.
Time-Dependent Cox Regression and Multicategory Exposure
MSM
Table 4 presents HRs of prescribing OCSs for asthma exacerba-
tions. Adjusting for time-dependent and baseline covariates in
the Cox model showed that LABA initiators were 34% more likely
to receive prescriptions for regular courses of OCSs than ICS
initiators (HR 1.34; 95% CI 1.27–2.02). Likewise, ICS/LABA initiators
were 17% more likely than ICS initiators to receive OCSs (HR 1.17;
95% CI, 1.04–2.3), but not different than LABA initiators (HR 0.7;
95% CI 0.4–1.64).
In the MSM, LABA initiators were found to be 14% more likely
than ICS initiators to receive OCSs (HR 1.14; 95% CI 1.03–1.22). Con-
versely, combination therapy initiators were less likely than LABA
initiators to receive OCSs (HR 0.23; 95% CI 0.1–0.34), but notrbations requiring OCS prescriptions.
Outcome
Short-course OCS
 SD No. of cases IR (95% CI)* TTE  SD
2  0.4 1226 9.8 (9.3–10.4) 352.1  0.4
2  5.1 27 18.5 (12.7–27.0) 341.3  5.0
5  2.0 116 14.8 (12.4–17.8) 347.4  1.8
BA, long-acting beta-agonist; OCS, oral corticosteroid; TTE, average
Fig. 3 – Product-limit survival estimates of prescribing (A) regular courses and (B) short courses of oral corticosteroids for the
treatment of asthma exacerbations. ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.
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Likewise, a similar trend was observed in prescribing short
courses of OCSs.
Although some of the causal effect identiﬁability assumptions
are not tested, Figure 4 illustrates the monthly distribution of
stabilized weights over the follow-up year. On average, the
weights have a mean of 1.02 compared with unstabilized weights
(2.33), indicating model satisfaction with positivity (experimental
treatment) assumption.Conclusions
Methods records of patients with asthma in the CPRD were used
to conduct a population-based cohort study to assess OCS
prescribing rates for asthma exacerbations after exposure to
inhaled LABA bronchodilators as monotherapy versus ICS-based
regimens. An extension of the MSM to this real-world scenario of
multicategory exposure was used, and exposure effects were
Table 4 – HRs of OCS prescriptions.
Model Outcome Exposure comparison HR 95% CI
Cox regression* OCS LABA vs. ICS 1.34 1.27–2.02
ICS/LABA vs. ICS 1.17 1.04–2.30
ICS/LABA vs. LABA 0.70 0.40–1.64
Short-course OCS LABA vs. ICS 1.47 1.22–2.44
ICS/LABA vs. ICS 1.00 0.66–2.10
ICS/LABA vs. LABA 0.91 0.81–1.35
MSM† OCS LABA vs. ICS 1.14 1.03–1.22
ICS/LABA vs. ICS 0.91 0.41–1.00
ICS/LABA vs. LABA 0.23 0.09–0.34
Short-course OCS LABA vs. ICS 1.10 1.07–1.18
ICS/LABA vs. ICS 0.38 0.12–0.66
ICS/LABA vs. LABA 0.50 0.14–0.78
CI, conﬁdence interval; Cox regression, time-dependent covariate Cox proportional hazards regression; HR, hazard ratio; ICS, inhaled
corticosteroid; LABA, long-acting beta-agonist; MSM, marginal structural model; OCS, oral corticosteroid.
* Adjusted for baseline year, index date, and time-dependent covariates.
† Adjusted for all covariates, including time-dependent confounders.
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model to test for the presence of time-dependent confounding
by asthma severity. The ﬁndings show that LABA monotherapy is
signiﬁcantly associated with a 10% to 14% increase in OCS
prescriptions for asthma exacerbations compared with ICS
monotherapy; however, prescribing ICS/LABA combination ther-
apy as a single-device or a separate-device combination is
associated with 9% to 62% and 50% to 77% decrease in OCS
prescriptions for asthma exacerbations compared with ICS
monotherapy and LABA monotherapy, respectively. This sug-
gests beneﬁcial effects when prescribing inhaled LABA broncho-
dilators as an add-on therapy to ICS monotherapy to control
asthma exacerbations. These ﬁndings are consistent with pub-
lished clinical trials, and in concordance with current recom-
mendations from asthma management guidelines [3,5,6]. One
meta-analysis comparing ICS/salmeterol combination therapy
with ICS monotherapy showed a signiﬁcant reduction in asthma
exacerbations requiring OCSs (risk difference 0.02; 95% CI 0.04
to 0.01) [25]. Another meta-analysis showed that combination
therapy is associated with less exacerbations requiring systemic
steroids (odds ratio 0.73; 95% CI 0.67–0.79) [26].
Most of the LABA initiators had controlled asthma, whereas
ICS/LABA combinations were rather equally prescribed to
patients with controlled (52%) and uncontrolled disease (48%) at
baseline. Anti-inﬂammatory LTRAs, however, were mostly pre-
scribed to initiators of LABA-based therapies than to initiators of
ICS monotherapy, suggesting that controller medications such as
LTRAs are necessary as add-on therapies to bronchodilator
formulations with LABAs, particularly monotherapy. In contrast,
xanthine bronchodilators were mainly prescribed to ICS mono-
therapy initiators.
This study has several limitations. Given the observational
nature of the study design, lack of randomization precludes equal
distribution of known and unknown confounders among expo-
sure groups. Although attempts were made to account for all
confounders, residual confounding due to unmeasured factors
cannot be completely excluded. Also, exchangeability (lack of
unmeasured confounding) assumption for the MSM was not
tested in this study; therefore, the estimated average causal
effect of LABA products on asthma morbidity should be inter-
preted with caution. Furthermore, the external validity of the
ﬁndings is limited to the UK population, which could affect
extrapolations to patients with asthma in other countries, espe-
cially regarding age and race information.It should be noted that the medication data in the CPRD are
prescribing rather than dispensing information, which imparts
difﬁculty in applying approaches to measure patients’ adherence
—especially because actual medication use by patient is
unknown. Low adherence to inhaled pharmaceutical dosage
forms, particularly ICSs, is a widely recognized problem [27].
Although Read Clinical Terms denoting a patient’s compliance
level with asthma medications and other pertinent information
were included in analyses, they were scarce.
Lack of information on over-the-counter product exposure
casts more limitations, especially when products affect asthma
medication choices or asthma outcomes, such as nonsteroidal
anti-inﬂammatory drugs, which could contribute to residual
confounding. Likewise, information about prescriptions issued
to patients in settings other than general practices are not
recorded, and therefore, time-dependent exposure might not
be fully categorized and exposure misclassiﬁcation might occur
when a patient received a prescription for his or her subsequent
exposure from an outpatient clinic or a hospital. In addition,
confounding misclassiﬁcation could happen because lung func-
tion tests were not used as a severity measure (for scarcity and
inconsistency), although the alternative asthma severity meas-
ures used are deemed sufﬁcient given the nature of the
database.
Time-dependent confounding by disease severity with
regard to exposure effect on OCS prescribing was evident when
CIs from the MSM did not overlap with corresponding intervals
from Cox regression models (Table 4); the lack of overlap is
explained by the presence of a link between previous exposure
status and current disease severity (dashed arrow in Fig. 5),
where previous ICS exposure inﬂuences current asthma
severity, which inﬂuences the decision to step up therapy by
the addition of LABAs, and current exposure also affects future
asthma severity, which also inﬂuences future therapy decision
of LABA discontinuation. This time-dependent confounding of
asthma severity affects the evaluation of the treatment effect of
interest.
In addition to binary exposure, the MSM can be applied to
multicategory exposure groups, and this study recommends
taking time-dependent confounding by disease severity into
consideration in asthma outcome studies. ICS/LABA combination
therapy had better asthma control than did either ICS mono-
therapy or LABA monotherapy alone. Inhaled LABA monotherapy
was associated with worsened asthma outcomes compared with
Fig. 4 – Distribution of (A) unstabilized and (B) stabilized weights estimated by MSM across study follow up year. MSM,
marginal structural model.
Fig. 5 – Asthma severity as time-dependent confounding between inhaled LABA and prescribing oral corticosteroids for
asthma exacerbations. ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; OCS, oral corticosteroid.
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against prescribing long-lasting beta-agonists as monotherapy to
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